When to Order TSH Receptor Antibodies
Order TSH receptor antibodies (TRAb) as first-line testing after confirming thyrotoxicosis biochemically (suppressed TSH with elevated free T4/T3), unless the clinical presentation is unambiguous with clear extrathyroidal signs of Graves' disease such as ophthalmopathy. 1
Diagnostic Algorithm for Thyrotoxicosis
Step 1: Initial Biochemical Confirmation
- Measure TSH first when thyrotoxicosis is clinically suspected
- If TSH is suppressed, measure free T4 and free T3 to confirm thyrotoxicosis and assess severity 1
Step 2: Determine Need for TRAb Testing
Skip TRAb testing if:
- Clinical presentation is unambiguous for Graves' disease, particularly when extrathyroidal manifestations are present:
- Graves' ophthalmopathy (proptosis, lid retraction, periorbital edema)
- Pretibial myxedema
- Thyroid acropachy
In these cases, the diagnosis is clinically evident and TRAb testing adds no value 1
Order TRAb testing when:
- Clinical presentation is atypical or unclear
- No extrathyroidal signs present
- Differential diagnosis includes toxic multinodular goiter, toxic adenoma, or thyroiditis
- Need to distinguish Graves' disease from other causes of thyrotoxicosis 1, 2
Why TRAb is Recommended First-Line
The guideline emphasizes TRAb over scintigraphy due to:
- Excellent sensitivity and specificity (>95%) for Graves' disease 3
- Easy accessibility and non-invasive nature
- Cost-effectiveness compared to imaging 1
Reserve thyroid scintigraphy only for:
- Rare cases where TRAb is negative but Graves' disease still suspected
- When alternative etiologies (toxic nodule, multinodular goiter) are suspected 1
Additional Clinical Scenarios Requiring TRAb Testing
Pregnancy-Related Indications
Order TRAb when:
- Pregnant women with current or previously treated Graves' disease
- TRAb ≥5 IU/L indicates increased risk of fetal/neonatal thyrotoxicosis requiring close monitoring 4
- Measure in third trimester to assess fetal risk 5
Treatment Decision-Making
Order TRAb to guide therapy:
- At diagnosis: TRAb >12 IU/L predicts 60% relapse risk at 2 years, 84% at 4 years 4
- After 12 months of antithyroid drugs: TRAb >7.5 IU/L predicts >90% relapse risk 4
- At cessation of therapy (18 months): TRAb >3.85 IU/L predicts >90% relapse risk 4
High TRAb levels favor definitive treatment (radioactive iodine or thyroidectomy) over continued medical management 4
Graves' Orbitopathy
Order TRAb when:
- Evaluating euthyroid or hypothyroid patients with suspected Graves' ophthalmopathy
- TRAb helps establish autoimmune etiology when thyroid function is normal 2, 6
- Elevated TRAb indicates need for steroid prophylaxis before radioactive iodine therapy to prevent orbitopathy progression 4
Hashimoto's Thyroiditis with Hypothyroidism
Consider TRAb when:
- Patients with Hashimoto's thyroiditis develop severe hypothyroidism with atrophic thyroid
- Blocking TRAb (TSBAb) may be contributing to hypothyroidism 3
Common Pitfalls to Avoid
Do not order both TRAb and TSI simultaneously - this represents redundant testing with 14-17% co-ordering rates nationally, resulting in 31-325% increased costs without clinical benefit 7. Either test is sufficient for diagnosis.
Do not routinely order thyroid ultrasound first-line for Graves' disease diagnosis - it may provide supplementary information but is not recommended as initial etiological testing 1
Do not skip TRAb in women of childbearing age - early identification of high relapse risk allows consideration of definitive treatment before pregnancy, avoiding antithyroid drug exposure in early pregnancy which carries congenital anomaly risk 4